Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir.

12 in total

Review 1. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Authors: R Douglas Bruce; David E Moody; Frederick L Altice; Marc N Gourevitch; Gerald H Friedland
Journal: Expert Rev Clin Pharmacol Date: 2013-05 Impact factor: 5.045

Review 2. A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products.

Authors: Andrew Stolbach; Karolina Paziana; Harry Heverling; Paul Pham
Journal: J Med Toxicol Date: 2015-09

3. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients.

Authors: Hartmut Stocker; Guido Kruse; Peter Kreckel; Christian Herzmann; Keikawus Arastéh; Jörg Claus; Heiko Jessen; Christiane Cordes; Bettina Hintsche; Frank Schlote; Lothar Schneider; Michael Kurowski
Journal: Antimicrob Agents Chemother Date: 2004-11 Impact factor: 5.191

4. Strategies to improve access to and utilization of health care services and adherence to antiretroviral therapy among HIV-infected drug users.

Authors: Chinazo O Cunningham; Nancy L Sohler; Nina A Cooperman; Karina M Berg; Alain H Litwin; Julia H Arnsten
Journal: Subst Use Misuse Date: 2011 Impact factor: 2.164

5. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.

Authors: E D Kharasch; P S Bedynek; S Park; D Whittington; A Walker; C Hoffer
Journal: Clin Pharmacol Ther Date: 2008-10 Impact factor: 6.875

6. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir.

Authors: Evan D Kharasch; Christine Hoffer; Dale Whittington; Alysa Walker; Pamela Sheffels Bedynek
Journal: Anesthesiology Date: 2009-03 Impact factor: 7.892

Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir.

Review 1. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Review 2. A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products.

3. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients.

4. Strategies to improve access to and utilization of health care services and adherence to antiretroviral therapy among HIV-infected drug users.

5. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.

6. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir.

7. Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir.

Review 8. Practical considerations for the clinical use of buprenorphine.

Review 9. Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Review 10. Polypharmacy in the HIV-infected older adult population.